Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study

OBJECTIVES: To assess the effectiveness of Neuroaspis plp10 nutritional supplement when added to interferon (IFN)-β treatment in patients with relapsing-remitting multiple sclerosis (RRMS). DESIGN: A 30-month phase III multicentre, randomised, double-blind, placebo-controlled trial. Randomisation st...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantzaris, Marios C, Bakirtzis, Christos, Grigoriadis, Nikolaos, Hadjigeorgiou, Georgios, Dardiotis, Efthimos, Loucaides, George, Ntzani, Evangelia, Markozannes, Georgios, Omorfos, Savvas, Valsasina, Paola, Messina, Roberta, Preziosa, Paolo, Rocca, Maria A, Patrikios, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639060/
https://www.ncbi.nlm.nih.gov/pubmed/36353267
http://dx.doi.org/10.1136/bmjno-2022-000334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639060/
https://www.ncbi.nlm.nih.gov/pubmed/36353267
http://dx.doi.org/10.1136/bmjno-2022-000334

Ejemplares similares